Difference between revisions of "Team:CSU CHINA/Composite Part"
| Line 7: | Line 7: | ||
| + | <h1>Composite Parts</h1> | ||
| + | <div class="block main-text main-text" > | ||
| − | |||
| − | |||
| − | |||
<p> | <p> | ||
We contributed to the Registry with one supportive part, ready to use in regulating expressions of other proteins . Function of the part was experimentally validated. | We contributed to the Registry with one supportive part, ready to use in regulating expressions of other proteins . Function of the part was experimentally validated. | ||
| Line 29: | Line 28: | ||
<br/> | <br/> | ||
<br/> | <br/> | ||
| − | + | </div> | |
</html> | </html> | ||
Revision as of 02:20, 18 October 2018
Composite Parts
We contributed to the Registry with one supportive part, ready to use in regulating expressions of other proteins . Function of the part was experimentally validated.
Promoter CMV can motivate the expression of GAL4-VP16 infusion protein which drives the expression of HSV-thymidine kinase (HSV-TK) to achieve the tumor killing effect as gene therapy.
